Alnylam (ALNY) announced that the first patient has been dosed in ZENITH, a global Phase 3 cardiovascular outcomes trial designed to evaluate the potential of zilebesiran, an investigational biannual subcutaneously administered RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. Zilebesiran works by targeting liver-expressed angiotensinogen, the most upstream precursor in the Renin-Angiotensin-Aldosterone System, which plays a key role in blood pressure regulation and impacts CV and renal health.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam announces results from HELIOS-B Phase 3 study of AMVUTTRA
- Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR
- Alnylam price target raised to $500 from $435 at RBC Capital
- Alnylam price target raised to $520 from $453 at BofA
- Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion